Aileron Therapeutics Inc./$RNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aileron Therapeutics Inc.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Ticker
$RNTX
Sector
Primary listing
Employees
10
Headquarters
Website
RNTX Metrics
BasicAdvanced
$36m
-
-$1.96
1.40
-
Price and volume
Market cap
$36m
Beta
1.4
52-week high
$2.40
52-week low
$1.02
Average daily volume
148k
Financial strength
Current ratio
0.7
Quick ratio
0.52
Profitability
EBITDA (TTM)
-21.93
Effective tax rate (TTM)
1.41%
Management effectiveness
Return on assets (TTM)
-31.75%
Return on equity (TTM)
-139.87%
Valuation
Price to book
-1.25
Price to tangible book (TTM)
-0.73
Price to free cash flow (TTM)
-1.676
Free cash flow yield (TTM)
-59.68%
Free cash flow per share (TTM)
-0.761
Growth
Earnings per share change (TTM)
-44.09%
3-year earnings per share growth (CAGR)
-31.21%
10-year earnings per share growth (CAGR)
-44.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aileron Therapeutics Inc. stock?
Aileron Therapeutics Inc. (RNTX) has a market cap of $36M as of April 30, 2026.
What is the P/E ratio for Aileron Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Aileron Therapeutics Inc. (RNTX) stock is 0 as of April 30, 2026.
Does Aileron Therapeutics Inc. stock pay dividends?
No, Aileron Therapeutics Inc. (RNTX) stock does not pay dividends to its shareholders as of April 30, 2026.
When is the next Aileron Therapeutics Inc. dividend payment date?
Aileron Therapeutics Inc. (RNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Aileron Therapeutics Inc.?
Aileron Therapeutics Inc. (RNTX) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.